Is Fulcrum Therapeutics, Inc. (FULC) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.2% / 30% | 64.7% / 30% | 0.2% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 1.2% / 33% | 64.7% / 33% | 0.2% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 1.8% / 33% | 96.2% / 33% | 0.3% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.2% / 33% | 64.7% / 33% | 0.2% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 1.8% / 33% | 96.2% / 33% | 0.3% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -25.3% | |
| Return on Assets (ROA) | -16.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$60M |
| Free Cash Flow | -$60M |
| Total Debt | $6M |
| Debt-to-Equity | 1.8 |
| Current Ratio | 27.4 |
| Total Assets | $366M |
Price & Trading
| Last Close | $6.94 |
| 50-Day MA | $9.20 |
| 200-Day MA | $8.78 |
| Avg Volume | 995K |
| Beta | 3.3 |
|
52-Week Range
$2.31
| |
About Fulcrum Therapeutics, Inc. (FULC)
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Fulcrum Therapeutics, Inc. (FULC) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Fulcrum Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Fulcrum Therapeutics, Inc.'s debt ratio?
Fulcrum Therapeutics, Inc.'s debt ratio is 1.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.8%.
What are Fulcrum Therapeutics, Inc.'s key financial metrics?
Fulcrum Therapeutics, Inc. has a market capitalization of $448M. Return on equity stands at -25.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.